Introduction: The Advisory Committee on Immunization Practices recommends a single dose of tetanus, diphtheria, and acellular pertussis vaccine (Tdap) for adults followed by tetanus and diphtheria toxoids (Td) booster doses every 10 years thereafter. This study assessed recent Td and Tdap vaccination among adult populations.
Methods: The 2013 Behavioral Risk Factor Surveillance System data were analyzed in 2015 to assess Td and Tdap vaccination coverage among adults at national and state levels. Multivariable logistic regression and predictive marginal models were performed to identify factors independently associated with vaccination.
Results: Overall, national vaccination coverage among adults aged ≥18 years for Td was 57.5% and for Tdap was 28.9%. Among states, Td vaccination coverage ranged from 47.8% in Nevada to 73.1% in Minnesota, and Tdap coverage ranged from 17.7% in Mississippi to 47.6% in Minnesota. Characteristics independently associated with an increased likelihood of Tdap vaccination among adults aged ≥18 years were younger age; being female; American Indian/Alaska Native race; being never married; higher education; not being in the workforce; reporting a household income ≥$75,000; living in the West or Midwest U.S.; reporting excellent, very good, good, or fair health; having health insurance; having a healthcare provider; having a routine checkup in the previous year; receipt of influenza vaccination in the previous year; and having ever received pneumococcal vaccination.
Conclusions: By 2013, Td and Tdap vaccination coverage were 57.5% and 28.9%, respectively. Coverage varied by state. Implementation of evidence-based programs is needed to improve Td and Tdap vaccination levels among adult populations.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5819000 | PMC |
| http://dx.doi.org/10.1016/j.amepre.2015.09.033 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Vaccine Acceptance Among Pregnant Women in Israel During COVID-19: Influences and Decision-Making Factors.
Vaccines (Basel)
December 2024
The Shamir Medical Center (Assaf Harofeh), Rishon LeZion, 4 Icet, Zrifin 7033001, Israel.
In response to the COVID-19 pandemic, Israel prioritized pregnant women for vaccination, recognizing them as a high-risk group. This study aims to explore factors influencing the acceptance of Influenza, Pertussis (T-dap), and COVID-19 vaccines among pregnant women, focusing on attitudes, social norms, perceived control, and risk perceptions. Additionally, the study compares acceptance patterns between traditional vaccines and the newer COVID-19 vaccine.
View Article and Find Full Text PDFAtrial Fibrillation after RSV Vaccination Among Older Adults.
Clin Infect Dis
December 2024
Division of Infectious Diseases and Global Public Health, University of California, San Diego, La Jolla, California, USA.
RSV vaccine clinical trials reported higher frequencies of atrial fibrillation in intervention groups compared to control. In this large, population-based, propensity-matched study, we found RSV vaccine was not associated with increased risk of new-onset or recurrent atrial fibrillation within 1-42 days compared to influenza or Tdap vaccines.
View Article and Find Full Text PDFA Model for Consolidating High-Risk Allergy Procedures in Clinic.
Ochsner J
January 2024
Department of Allergy and Immunology, Ochsner Clinic Foundation, New Orleans, LA.
Allergists perform a range of procedures with inherent risks of anaphylaxis. This study developed risk assessments for various procedures performed at our specialized referral center based on the frequency of epinephrine use during these procedures. During a 5.
View Article and Find Full Text PDFDecay Rates of Maternal Tetanus, Diphtheria, and Pertussis Antibody Levels in Early and Moderate-to-Late Preterm and Term Infants at Birth and at Two Months.
Open Forum Infect Dis
January 2025
Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands.
A post hoc analysis of maternally derived antibodies at birth and age 2 months following second trimester maternal Tdap vaccination between 20 and 24 weeks' gestational age (GA) showed a faster decay rate of Tdap-related immunoglobulin G in early preterms born before 32 weeks' GA compared with moderate-to-late preterms and full-terms. This is different from previous studies and merits further research.
View Article and Find Full Text PDFSafety and immunogenicity of an acellular pertussis vaccine containing genetically detoxified pertussis toxin administered to pregnant women living with and without HIV and their newborns (WoMANPOWER): a randomised controlled trial in Uganda.
Lancet Glob Health
January 2025
Centre for Neonatal and Paediatric Infection and Vaccine Institute, City St George's, University of London, London, UK; Makerere University-Johns Hopkins University Research Collaboration, Kampala, Uganda; UK Health Security Agency, Salisbury, UK.
Article Synopsis
- The study investigates the safety and immunogenicity of a TdaP vaccine for pregnant women living with HIV, aiming to protect infants from severe pertussis disease.
- Conducted in Uganda, the trial randomly assigned 181 women (HIV-positive and HIV-negative) to receive either the TdaP or Td vaccine, evaluating immune responses in infants post-delivery.
- Findings will provide valuable insights into the vaccine's effectiveness and safety for this specific population, contributing to better health outcomes for mothers and their babies.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!